Jan 11, 2024 / 08:00PM GMT
Josh Bowers JPMorgan-Analyst
Good afternoon, everyone. Welcome to the final day of the JPMorgan conference. I'm Josh Bowers from the London healthcare team.
It's my absolute pleasure today to welcome Dr. Markku to present to you today. We'll have 20, 25 minutes, and then we'll open up to some questions. And then he'll stick around afterwards if you have any follow-ups.
And with that, I'll hand it over to you, Markku.
Markku Jalkanen Faron Pharmaceuticals Oy-CEO&Founder
Thank you, Joshua. I understand that this is really a privilege. So I would really thank also JPMorgan management, really, giving this opportunity to talk about Farron.
As you may already notice, we are a dualistic company, both in London, AIM, and then Helsinki First North. And obviously, I want to show this disclaimer really. Because I'm going to say something about the future of the company as well.
So I believe that we are the world leader at the moment in reprogramming myeloid cells. Why we want to do that? They are
Faron Pharmaceuticals Oy at JPMorgan Healthcare Conference Transcript
Jan 12, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers